Elevation Oncology (ELEV) Stock Price, News & Analysis

Company Overview

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $0.57 to $0.60
• 50-Day Range: $0.52 to $0.75
• 52-Week Range: $0.50 to $5.83
• Volume: 944,319 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $33.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.20
• Consensus Rating: Buy

Elevation Oncology Stock Analysis - MarketRank™

Elevation Oncology scored higher than 29% of companies evaluated by MarketBeat, and ranked 817th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Elevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Elevation Oncology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Elevation Oncology are expected to decrease in the coming year, from ($0.85) to ($0.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elevation Oncology is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elevation Oncology is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elevation Oncology has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.82% of the float of Elevation Oncology has been sold short.

Short Interest Ratio / Days to Cover

Elevation Oncology has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Elevation Oncology has recently increased by 0.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elevation Oncology does not currently pay a dividend.

Dividend Growth

Elevation Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.82% of the float of Elevation Oncology has been sold short.

Short Interest Ratio / Days to Cover

Elevation Oncology has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Elevation Oncology has recently increased by 0.33%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 7 people have searched for ELEV on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elevation Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.10% of the stock of Elevation Oncology is held by insiders.

Percentage Held by Institutions

83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELEV Stock Analysis - Frequently Asked Questions

How have ELEV shares performed this year?

Elevation Oncology's stock was trading at $0.5370 at the beginning of 2024. Since then, ELEV shares have increased by 6.1% and is now trading at $0.57.
View the best growth stocks for 2024 here.

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.02.

When did Elevation Oncology IPO?

Elevation Oncology (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

How do I buy shares of Elevation Oncology?

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Elevation Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 12/30/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELEV
• CUSIP: N/A
• CIK: 1783032
• Web: www.elevationoncology.com
• Phone: 716-371-1125
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.20
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +1,145.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-45,700,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -59.73%
• Return on Assets: -40.05%

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 17.77
• Quick Ratio: 17.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 59,119,000
• Free Float: 54,330,000
• Market Cap: $34.16 million
• Optionable: Optionable
• Beta: 1.24